- Home
- HST vs INCY Comparison
HST vs INCY Comparison
Compare HST & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HST
- INCY
- Stock Information
- Founded
- HST 1927
- INCY 1991
- Country
- HST United States
- INCY United States
- Employees
- HST N/A
- INCY N/A
- Industry
- HST Real Estate Investment Trusts
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- HST Real Estate
- INCY Health Care
- Exchange
- HST Nasdaq
- INCY Nasdaq
- Market Cap
- HST 11.9B
- INCY 13.4B
- IPO Year
- HST N/A
- INCY 1993
- Fundamental
- Price
- HST $13.66
- INCY $58.21
- Analyst Decision
- HST Buy
- INCY Hold
- Analyst Count
- HST 15
- INCY 20
- Target Price
- HST $19.17
- INCY $74.00
- AVG Volume (30 Days)
- HST 12.7M
- INCY 2.3M
- Earning Date
- HST 04-30-2025
- INCY 04-29-2025
- Dividend Yield
- HST 6.59%
- INCY N/A
- EPS Growth
- HST N/A
- INCY N/A
- EPS
- HST 0.99
- INCY 0.15
- Revenue
- HST $5,691,000,000.00
- INCY $4,241,216,999.00
- Revenue This Year
- HST $4.71
- INCY $12.21
- Revenue Next Year
- HST $2.84
- INCY $9.20
- P/E Ratio
- HST $13.80
- INCY $345.39
- Revenue Growth
- HST 7.03
- INCY 14.76
- 52 Week Low
- HST $12.22
- INCY $50.35
- 52 Week High
- HST $19.87
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- HST 43.39
- INCY 40.69
- Support Level
- HST $13.29
- INCY $57.05
- Resistance Level
- HST $14.08
- INCY $59.95
- Average True Range (ATR)
- HST 0.79
- INCY 2.76
- MACD
- HST 0.06
- INCY 0.18
- Stochastic Oscillator
- HST 58.06
- INCY 46.45
About HST Host Hotels & Resorts Inc.
Host Hotels & Resorts owns 81 predominantly urban and resort upper-upscale and luxury hotel properties representing over 43,000 rooms, mainly in the United States. Host recently sold off the company's interests in a joint venture owning a portfolio of hotels throughout Europe and also sold other joint ventures that owned properties in Asia and the United States. The majority of Host's portfolio operates under the Marriott and Starwood brands.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.